In fact, CD163+ “tumor-promoting” M2 macrophages which can be abundant in the microenvironment of colorectal carcinomas are activated by cetuximab and in turn they release anti-inflammatory and tumor-promoting mediators, including IL-10 and VEGF (Pander et al., 2011). Here, VEGFA is linked to neoplasm.